Biotech Bounceback: Private Equity and the Life Sciences Resurgence

After years of a bear market, the life sciences sector has come roaring back. With strong fundamentals and record deal activity, we see a compelling backdrop for private investment into life sciences.

Key Takeaways

1

Scientific Breakthroughs and an Attractive Investment Backdrop

After a challenging period from 2021–2025, we see positive momentum in the life sciences sector. Continued scientific breakthroughs that are now being accelerated with AI are enabling new medicines that can meaningfully improve patient outcomes at a time when aging demographics are increasing demand. Lower interest rates, a more stable geopolitical backdrop and easing concerns regarding biopharma-related policy have all contributed to a more favorable environment.

2

Big Pharma Pipeline Gaps Drive M&A and Exit Optionality

Industry giants are deploying their balance sheets to acquire innovative drug pipelines to mitigate potential revenue erosion caused by looming losses of drug exclusivity. We expect this trend to continue, providing opportunities for biotech companies developing novel medicines with demonstrated clinical proof of concept. M&A also presents a potentially more reliable exit path than the IPO market for private equity investors.

3

Private Equity, Value Creation Potential, and Diversification Appeal

Private life sciences investment capital continues to grow as an asset class with the emergence and deepening of mid-stage and later-stage investment pools to support life sciences innovation across the life cycle. We see outsized growth driven by strong fundamentals (e.g. robust innovation and increasing demand) but also see investment managers choosing to pursue life sciences strategies due to the unique risk/reward profile of the category and uncorrelated nature of investment.

Scientific Breakthroughs and an Attractive Investment Backdrop

The life sciences sector is experiencing a surge of innovation as the industry evolves from a focus of sickness management to a paradigm of proactive, predictive, and personalized health. This includes the maturation of advanced modalities and novel delivery mechanisms such as cell and gene therapy, antibody drug conjugates, and next-generation vaccine platforms. In neuroscience, we see the development of novel antidepressants and drugs to reduce anxiety. Oncology is reaching new levels through personalized cancer vaccines and targeted therapies. Advancements in immunology for a host of inflammatory conditions coupled with progress in treating rare diseases via personalized gene therapies, underscore a transformative era of life sciences innovation. This comes at a time of aging demographics. Globally, individuals over the age of 65 are set to double from 800 million to 1.6bn by 2050, with the US and Europe expected to see the largest increases.¹ We believe this will drive higher healthcare spending and greater demand for new medicines as people seek to live better for longer.

Alongside continued scientific breakthroughs, there has been a reduction in political and regulatory uncertainty due to stabilizing commentary and actions taken by the US administration. Concerns over drug pricing eased following late 2025 Most Favored Nation (MFN) agreements between the US government and industry leaders including Pfizer, AstraZeneca, Merck, Eli Lilly, and Novo Nordisk, providing greater clarity around pricing and supporting commitments to expand US-based manufacturing and R&D. While the evolving Section 232 pharmaceutical tariff framework introduces new considerations for parts of the industry, it may also accelerate onshore investment, strengthen the competitiveness of the US biotechnology ecosystem, and reinforce demand for external innovation through partnerships, licensing activity, and M&A. Despite concerns regarding regulatory volatility and personnel turnover in 2025, FDA approval activity accelerated through the second half of 2025 and into 2026, signaling continued agency effectiveness and a more constructive operating environment.² The sector’s recovery is evident in public markets, with the XBI up 86% over the past year, reaching 97% of the market's record high and substantially outperforming the broader healthcare sector. Fund flows have also turned positive following several years of weaker activity. In H1 2026, biotechnology equity funding reached $11.9bn across 88 deals, representing a 49% increase in total deployed capital compared with H1 2025. This backdrop of accelerating scientific breakthroughs, combined with a stabilizing regulatory environment, supports the life sciences sector and its continued growth trajectory in 2026 and beyond.

Big Pharma Pipeline Gaps Drive M&A and Exit Optionality for Private Equity

Some of the best-selling drugs in the world are facing a loss of exclusivity in the upcoming years in what the sector calls “the patent cliff.”³ This is driving a robust level of M&A activity in 2026, continuing a trend which started in fall of 2025. Activity has been concentrated in "bolt-on" deals under $15bn.⁴ GSK’s acquisition of Nuvalent (oncology treatments) and AbbVie’s acquisition of Apogee Therapeutics (immunological and inflammatory diseases) show that dealmaking activity is well positioned to continue in the back half of 2026 into 2027.⁵ Big Pharma’s drive to replenish pipelines through M&A presents a potentially more reliable exit path for investors in life sciences companies compared to relying solely on the IPO market.

2026 exceeded historic biopharma bolt-on M&A values… Life sciences private equity M&A volume declined after a 2019 peak but has rebounded since 2023, driven increasingly by transactions larger than $5bn.

Life sciences private equity M&A volume declined after a 2019 peak but has rebounded since 2023, driven increasingly by transactions larger than $5bn.

…patent-related revenue pressures are expected to accelerate Cumulative life sciences revenue exposed to loss of exclusivity is projected to rise from about $30bn in 2026 to more than $650bn by 2036, creating a growing need for replacement therapies and innovation.

Cumulative life sciences revenue exposed to loss of exclusivity is projected to rise from about $30bn in 2026 to more than $650bn by 2036, creating a growing need for replacement therapies and innovation.

Source: LHS: Goldman Sachs Biotech Sector Team M&A Database, as of July 2026. Bolt-on is defined as deals under $15bn. RHS: Jefferies Biopharma LOE report, as of July 2026.

Private Equity, Value Creation Potential, and Diversification Appeal

Value creation in the pharmaceutical sector spans from industry giants to innovative smaller biotechs. Eli Lilly became the first pharma company to hit a $1tn market cap in November 2025, fueled by the massive success of its GLP-1 drugs for diabetes and obesity.⁶ Lilly leveraged this growth to fund strategic M&A, strengthening its pipeline. Conversely, smaller firms like Nuvalent Inc. drive value through breakthroughs; and in July 2026, GSK acquired Nuvalent for $10.6bn—at a 40% premium—to gain access to its lung cancer therapeutics to target tumors that acquired resistance mutations and have spread into the central nervous system.⁷

We believe we are in the early innings of the AI transformation of life sciences. We expect continued evolution in the way companies discover, develop, and deliver medicines to patients. For the foreseeable future, we expect earlier-stage biotech company valuations will remain grounded in tangible assets like intellectual property and preclinical/clinical trial data, with value inflection points tied to scientific/clinical milestones, regulatory approvals, and projected peak sales of drug candidates. Consequently, private equity life sciences investors will remain focused on achieving clinical milestones and reasonable valuations compared to managing the volatility of the public markets or untethered valuations of AI/technology industries.

In addition to high value creation potential, life sciences is also a defensive asset class that is generally uncorrelated with broader market performance. The drivers of life sciences innovation, utilization, and payment are not linked to economic or market cycles. Companies succeed based on the outcomes of scientific and clinical experiments. Utilization is a function of underlying disease incidence and prevalence, while reimbursement comes from third-party payors such as insurance companies and governments. We believe these idiosyncratic characteristics make life sciences an attractive sector for investment, offering investors significant growth potential, uncorrelated returns, and favorable industry dynamics.

New Era for Life Sciences

The life sciences sector has entered a transformative era, underpinned by powerful synergies of scientific innovation, regulatory clarity, and "patent cliffs" compelling Big Pharma to replenish pipelines. Beyond deal dynamics, the industry’s fundamental reliance on achieving clinical milestones—rather than macroeconomic cycles—provides a unique, uncorrelated risk-return profile. In our view, private equity investors with strong capabilities to source deals and drive value creation will be well positioned to succeed.

1. UN, Goldman Sachs Global Investment Research. As of November 2024.
2. DCAT Value Chain Insights. As of July 9, 2026.
3. CNBC. As of January 7, 2026.
4. Goldman Sachs Global Investment Research. As of April 8, 2026.
5. Gilead Sciences, J.P. Morgan, Q2 2026 Biopharma Licensing and Venture Report. As of July 2026.
6. Reuters. As of November 21, 2025.
7. Novartis, Reuters. As of February 7, 2026

Author(s)

Amit Sinha

Global Head and Chief Investment Officer, Life Sciences Investing

Jessica Davis

Vice President, Life Sciences Alternative Capital Formation

Glossary-See Glossary for definition of terms used in reference to Products

Risk considerations and disclosures

Views and opinions expressed are for informational purposes only and do not constitute a recommendation by Goldman Sachs Asset Management to buy, sell, or hold any security. Views and opinions are current as of the date of this publication and may be subject to change, they should not be construed as investment advice.

Individual portfolio management teams for Goldman Sachs Asset Management may have views and opinions and/or make investment decisions that, in certain instances, may not always be consistent with the views and opinions expressed herein.

THESE MATERIALS ARE PROVIDED SOLELY ON THE BASIS THAT THEY WILL NOT CONSTITUTE INVESTMENT ADVICE AND WILL NOT FORM A PRIMARY BASIS FOR ANY PERSON'S OR PLAN'S INVESTMENT DECISIONS, AND GOLDMAN SACHS IS NOT A FIDUCIARY WITH RESPECT TO ANY PERSON OR PLAN BY REASON OF PROVIDING THE MATERIAL OR CONTENT HEREIN. PLAN FIDUCIARIES SHOULD CONSIDER THEIR OWN CIRCUMSTANCES IN ASSESSING ANY POTENTIAL INVESTMENT COURSE OF ACTION.

THIS MATERIAL DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO.

Prospective investors should inform themselves as to any applicable legal requirements and taxation and exchange control regulations in the countries of their citizenship, residence or domicile which might be relevant.

Past performance does not guarantee future results, which may vary. The value of investments and the income derived from investments will fluctuate and can go down as well as up. A loss of principal may occur.

This information discusses general market activity, industry or sector trends, or other broad-based economic, market or political conditions and should not be construed as research or investment advice. This material has been prepared by Goldman Sachs Asset Management and is not financial research nor a product of Goldman Sachs Global Investment Research (GIR). It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed may differ from those of Goldman Sachs Global Investment Research or other departments or divisions of Goldman Sachs and its affiliates. Investors are urged to consult with their financial advisors before buying or selling any securities. This information may not be current and Goldman Sachs Asset Management has no obligation to provide any updates or changes.

There is no guarantee that objectives will be met.

Investment in a private investment product is suitable only for sophisticated investors for whom such investment does not constitute a complete investment program and who fully understand, and are willing to assume, the risks involved in such product. Private equity investments, by their nature, involve a substantial degree of risk, including the risk of total loss of an investor’s capital.

Nothing contained in this overview shall be relied upon as a promise or representation regarding the historic, current or future position or performance of any GS Asset & Wealth Management Private product or any investment referenced herein. In particular, no representation or warranty is made with respect to the reasonableness of any estimates, forecasts, prospects or returns, which should be regarded as illustrative only, or that any profits will be realized. Past performance is not a guide to future performance and the value of investments and the income derived from those investments can go down as well as up. Future returns are not guaranteed and a total loss of principal may occur.

The information provided in this overview should not be considered a recommendation to purchase or sell any particular security and should not be relied upon in whole or in part in making an investment decision or evaluating an investment or for any other purpose.

This information discusses general market activity, industry or sector trends, or other broad-based economic, market or political conditions and should not be construed as research or investment advice. Economic and market forecasts presented herein reflect our judgment as of the date of this presentation and are subject to change without notice. Actual data will vary and may not be reflected here. These forecasts are subject to high levels of uncertainty that may affect actual performance. Accordingly, these forecasts should be viewed as merely representative of a broad range of possible outcomes. These forecasts are estimated, based on assumptions, and are subject to significant revision and may change materially as economic and market conditions change. Goldman Sachs has no obligation to provide updates or changes to these forecasts. These forecasts are not a reliable indicator of future performance.

Goldman Sachs does not provide legal, tax, or regulatory advice to prospective investors in any product, and each prospective investor is urged to discuss any prospective investment in a product with its legal, tax, and regulatory advisers in order to make an independent determination of the suitability and consequences of such an investment.

United States: In the United States, this material is offered by and has been approved by Goldman Sachs Asset Management, L.P., which is a registered investment adviser with the Securities and Exchange Commission.

United Kingdom: In the United Kingdom, this material is a financial promotion and has been approved by Goldman Sachs Asset Management International, which is authorized and regulated in the United Kingdom by the Financial Conduct Authority.

European Economic Area (EEA): This marketing communication is disseminated by Goldman Sachs Asset Management B.V., including through its branches (“GSAM BV”). GSAM BV is authorised and regulated by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten, Vijzelgracht 50, 1017 HS Amsterdam, The Netherlands) as an alternative investment fund manager (“AIFM”) as well as a manager of undertakings for collective investment in transferable securities (“UCITS”). Under its licence as an AIFM, the Manager is authorized to provide the investment services of (i) reception and transmission of orders in financial instruments; (ii) portfolio management; and (iii) investment advice. Under its licence as a manager of UCITS, the Manager is authorized to provide the investment services of (i) portfolio management; and (ii) investment advice. Information about investor rights and collective redress mechanisms are available on am.gs.com/policies-and-governance. Capital is at risk. Any claims arising out of or in connection with the terms and conditions of this disclaimer are governed by Dutch law.

In the European Union, this material has been approved by either Goldman Sachs Asset Management Funds Services Limited, which is regulated by the Central Bank of Ireland or Goldman Sachs Asset Management B.V, which is regulated by The Netherlands Authority for the Financial Markets (AFM).

Switzerland: For Qualified Investor use only – Not for distribution to general public. This is marketing material. This document is provided to you by Goldman Sachs Asset Management Schweiz Gmbh. Any future contractual relationships will be entered into with affiliates of Goldman Sachs Asset Management Schweiz Gmbh, which are domiciled outside of Switzerland. We would like to remind you that foreign (Non-Swiss) legal and regulatory systems may not provide the same level of protection in relation to client confidentiality and data protection as offered to you by Swiss law.

Asia excluding Japan: Please note that neither Goldman Sachs Asset Management (Hong Kong) Limited (“GSAMHK”) or Goldman Sachs Asset Management (Singapore) Pte. Ltd. (Company Number: 201329851H ) (“GSAMS”) nor any other entities involved in the Goldman Sachs Asset Management business that provide this material and information maintain any licenses, authorizations or registrations in Asia (other than Japan), except that it conducts businesses (subject to applicable local regulations) in and from the following jurisdictions: Hong Kong, Singapore, India and China. This material has been issued for use in or from Hong Kong by Goldman Sachs Asset Management (Hong Kong) Limited and in or from Singapore by Goldman Sachs Asset Management (Singapore) Pte. Ltd. (Company Number: 201329851H).

Australia: This material is distributed by Goldman Sachs Asset Management Australia Pty Ltd ABN 41 006 099 681, AFSL 228948 (‘GSAMA’) and is intended for viewing only by wholesale clients for the purposes of section 761G of the Corporations Act 2001 (Cth). This document may not be distributed to retail clients in Australia (as that term is defined in the Corporations Act 2001 (Cth)) or to the general public. This document may not be reproduced or distributed to any person without the prior consent of GSAMA. To the extent that this document contains any statement which may be considered to be financial product advice in Australia under the Corporations Act 2001 (Cth), that advice is intended to be given to the intended recipient of this document only, being a wholesale client for the purposes of the Corporations Act 2001 (Cth). Any advice provided in this document is provided by either of the following entities. They are exempt from the requirement to hold an Australian financial services licence under the Corporations Act of Australia and therefore do not hold any Australian Financial Services Licences, and are regulated under their respective laws applicable to their jurisdictions, which differ from Australian laws. Any financial services given to any person by these entities by distributing this document in Australia are provided to such persons pursuant to the respective ASIC Class Orders and ASIC Instrument mentioned below.

Goldman Sachs Asset Management, LP (GSAMLP), Goldman Sachs & Co. LLC (GSCo), pursuant ASIC Class Order 03/1100; regulated by the US Securities and Exchange Commission under US laws.
Goldman Sachs Asset Management International (GSAMI), Goldman Sachs International (GSI), pursuant to ASIC Class Order 03/1099; regulated by the Financial Conduct Authority; GSI is also authorized by the Prudential Regulation Authority, and both entities are under UK laws.
Goldman Sachs Asset Management (Singapore) Pte. Ltd. (GSAMS), pursuant to ASIC Class Order 03/1102; regulated by the Monetary Authority of Singapore under Singaporean laws
Goldman Sachs Asset Management (Hong Kong) Limited (GSAMHK), pursuant to ASIC Class Order 03/1103 and Goldman Sachs (Asia) LLC (GSALLC), pursuant to ASIC Instrument 04/0250; regulated by the Securities and Futures Commission of Hong Kong under Hong Kong laws

No offer to acquire any interest in a fund or a financial product is being made to you in this document. If the interests or financial products do become available in the future, the offer may be arranged by GSAMA in accordance with section 911A(2)(b) of the Corporations Act. GSAMA holds Australian Financial Services Licence No. 228948. Any offer will only be made in circumstances where disclosure is not required under Part 6D.2 of the Corporations Act or a product disclosure statement is not required to be given under Part 7.9 of the Corporations Act (as relevant).

FOR DISTRIBUTION ONLY TO FINANCIAL INSTITUTIONS, FINANCIAL SERVICES LICENSEES AND THEIR ADVISERS. NOT FOR VIEWING BY RETAIL CLIENTS OR MEMBERS OF THE GENERAL PUBLIC.

Canada: This presentation has been communicated in Canada by GSAM LP, which is registered as a portfolio manager under securities legislation in all provinces of Canada and as a commodity trading manager under the commodity futures legislation of Ontario and as a derivatives adviser under the derivatives legislation of Quebec. GSAM LP is not registered to provide investment advisory or portfolio management services in respect of exchange-traded futures or options contracts in Manitoba and is not offering to provide such investment advisory or portfolio management services in Manitoba by delivery of this material.

Japan: This material has been issued or approved in Japan for the use of professional investors defined in Article 2 paragraph (31) of the Financial Instruments and Exchange Law (“FIEL”). Also, Any description regarding investment strategies on collective investment scheme under Article 2 paragraph (2) item 5 or item 6 of FIEL has been approved only for Qualified Institutional Investors defined in Article 10 of Cabinet Office Ordinance of Definitions under Article 2 of FIEL.

Compliance code: 528594-OTU-2598131

Date of first use: September 01, 2026